Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22631753 | 0.89 | CYP2D6 (0.45) | CYP2D6KDM4E | |
| SCHEMBL11982030 | 0.82 | CYP2D6 (0.69) | CYP2D6KDM4E | |
| SCHEMBL22448783 | 0.81 | CYP2D6 (0.38) | CYP2D6 | |
| SCHEMBL19228115 | 0.79 | CYP2D6 (0.36) | CYP2D6KDM4E | |
| SCHEMBL22448787 | 0.79 | CYP2D6 (0.36) | CYP2D6 | |
| SCHEMBL3645133 | 0.79 | CYP2D6 (0.77) | CYP2D6KDM4E | |
| SCHEMBL22631917 | 0.78 | CYP2D6 (0.35) | CYP2D6 | |
| SCHEMBL19285969 | 0.78 | CYP2D6 (0.35) | CYP2D6 | |
| SCHEMBL23544062 | 0.78 | CYP2D6 (0.37) | CYP2D6 | |
| SCHEMBL8583588 | 0.76 | CYP2D6 (0.60) | CYP2D6KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827583-B2 | Vegetable oil-based material as a substitute for carnauba wax | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| EP-4205767-A1 | DRUG-LOADED MACROMOLECULE AND PREPARATION METHOD THEREFOR | Shanghai Senhui Medicine Co., Ltd. (CN) | 2023-07-05 | — | — | EP | disclosed |
| US-20220220066-A1 | NOVEL VEGETABLE OIL-BASED MATERIAL AS A SUBSTITUTE FOR CARNAUBA WAX | UNIV IOWA STATE RES FOUND INC (US) | 2022-07-14 | — | — | US | disclosed |
| WO-2021213492-A1 | DRUG-CARRYING MACROMOLECULE AND PREPARATION METHOD THEREFOR | 上海森辉医药有限公司 (CN) | 2021-10-28 | — | — | WO | disclosed |
| US-11130900-B2 | Method for improving cement toughness | SAUDI ARABIAN OIL COMPANY (SA) | 2021-09-28 | — | — | US | disclosed |
| US-20210024806-A1 | METHOD FOR IMPROVING CEMENT TOUGHNESS | ARAMCO SERVICES COMPANY | 2021-01-28 | — | — | US | disclosed |
| US-20200390901-A1 | CHEMOSELECTIVE THIOL-CONJUGATION WITH ALKENE OR ALKYNE-PHOSPHONOTHIOLATES AND - PHOSPHONATES | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) | 2020-12-17 | — | — | US | disclosed |
| US-10851046-B2 | Vegetable oil-based material as a substitute for carnauba wax | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-10836950-B1 | Method for improving cement toughness | SAUDI ARABIAN OIL COMPANY (SA) | 2020-11-17 | — | — | US | disclosed |
| EP-2052011-B1 | TARGETED POLYLYSINE DENDRIMER THERAPEUTIC AGENT | STARPHARMA PTY LTD (AU) | 2020-11-04 | — | — | EP | disclosed |
| US-9610322-B2 | Macrocyclic insulin-degrading enzyme (IDE) inhibitors and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-04-04 | — | — | US | disclosed |
| US-20150368280-A1 | HIGH REFRACTIVE INDEX ACRYLIC COMPOUND AND METHOD FOR PREPARING THE SAME | SAMSUNG SDI CO., LTD. (KR) | 2015-12-24 | — | — | US | disclosed |
| WO-2012034116-A2 | SMALL MOLECULES AS EPIGENETIC MODULATORS OF LYSINE-SPECIFIC DEMETHYLASE 1 AND METHODS OF TREATING DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-03-15 | — | — | WO | disclosed |
| US-20110045100-A1 | Antimalarial Quinolines and Methods of Use Thereof | GEORGETOWN UNIVERSITY (US) | 2011-02-24 | — | — | US | disclosed |
| US-20090137550-A1 | Novel Compounds | GLAXO GROUP LIMITED | 2009-05-28 | — | — | US | disclosed |
| US-20090005401-A1 | Novel Compounds | GLAXO GROUP LIMITED | 2009-01-01 | — | — | US | disclosed |
| WO-2008145836-A2 | CATALYTIC COMPOSITION INCLUDING METAL NANOPARTICLES CONTAINING A NITROGEN LIGAND IN AN IONIC LIQUID, METHOD FOR PREPARING SAME AND METHOD FOR HYDROGENATING AN OLEFINIC LOAD | I.F.P. (FR) | 2008-12-04 | — | — | WO | disclosed |
| US-20080175881-A1 | Blood-contacting medical devices for the release of nitric oxide and anti-restenotic agents | BOSTON SCIENTIFIC SCIMED, INC. | 2008-07-24 | — | — | US | disclosed |
| WO-2007082331-A1 | MODIFIED MACROMOLECULE | STARPHARMA PTY LIMITED (AU) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007045010-A1 | INHIBITORY COMPOUNDS | STARPHARMA PTY LIMITED (AU) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390901-A1 | CHEMOSELECTIVE THIOL-CONJUGATION WITH ALKENE OR ALKYNE-PHOSPHONOTHIOLATES AND - PHOSPHONATES | ACP1, PTMS, ALG1 | CYP2D6 4125/4885KDM4E 4051/4885 |
| US-20150368280-A1 | HIGH REFRACTIVE INDEX ACRYLIC COMPOUND AND METHOD FOR PREPARING THE SAME | RAD51, HRH3, C5 | CYP2D6 3199/4885KDM4E 3949/4885 |
| US-11827583-B2 | Vegetable oil-based material as a substitute for carnauba wax | FASN, C5, ACSL1 | CYP2D6 3175/4885KDM4E 3479/4885 |
| US-10851046-B2 | Vegetable oil-based material as a substitute for carnauba wax | FASN, C5, ACSL1 | CYP2D6 3175/4885KDM4E 3479/4885 |
| US-20110045100-A1 | Antimalarial Quinolines and Methods of Use Thereof | NQO2, QTRT1, QTRT2 | CYP2D6 639/4885KDM4E 1366/4885 |
| US-20090005401-A1 | Novel Compounds | MAPKAPK2, CREBBP, MAPK8 | CYP2D6 3603/4885KDM4E 3011/4885 |
| US-20220220066-A1 | NOVEL VEGETABLE OIL-BASED MATERIAL AS A SUBSTITUTE FOR CARNAUBA WAX | FASN, ACSL1, C5 | CYP2D6 3613/4885KDM4E 3700/4885 |
| US-20090137550-A1 | Novel Compounds | MAPKAPK2, CREBBP, MAPK8 | CYP2D6 3603/4885KDM4E 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.